Company Filing History:

9 out of 46

Pierre Fabre S.a.

Pierre Fabre Medicament

patents

Years Active: 1976-1989

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4851411 - 5-monoaryl as.-triazin-3-ones substituted in 2-position, and their use (1989-07-25),

2. 4605654 - 2-(arylalkyloxymethyl)morpholines and the central nervous system (1986-08-12),

3. 4478836 - 1-Aryl 2-aminomethyl cyclopropane carboxyamide (Z) derivatives and their (1984-10-23),

4. 4476061 - 2'-(Orthochlorobenzoyl)-4'-chloroglycylanilides (1984-10-09),

5. 4409241 - Method of treating anxiety with (1983-10-11),

6. 4382930 - 2'-(Orthochlorobenzoyl)-4'-chloroglycylanilides, compositions thereof, (1983-05-10),

7. 4380667 - 2'-(Orthochlorobenzoyl)-4'-chloroglycylanilides, compositions thereof, (1983-04-19),

8. 4372975 - Substituted 2-benzoyl-4-chloroglycinanilide derivatives, a process for (1983-02-08),

9. 4370347 - Method of treating anxiety with (1983-01-25),

10. 4188387 - Amino-aryl 1,24-triazines useful in the treatment of diverse pain (1980-02-12),

11. 3958002 - Medicaments having psychotropic properties (antitussives) (1976-05-18),

Title: Trailblazing Inventor: Antoine Stenger

Introduction: Antoine Stenger, a visionary inventor hailing from Castres, France, has made significant contributions to the field of innovation with an impressive portfolio of 11 patents. His latest inventions, which include new 5-monoaryl as.-triazin-3-ones and 2-(arylalkyloxymethyl)morpholines for medicinal purposes, showcase his dedication to improving healthcare and pushing the boundaries of scientific discovery.

Latest Patents: Antoine Stenger's groundbreaking patents encompass a range of pharmaceutical compounds aimed at treating disorders of the central nervous system. His innovative approach to drug development is evident in the formulas he has created, such as the 5-monoaryl as.-triazin-3-ones substituted in 2-position and the 2-(arylalkyloxymethyl)morpholine derivatives.

Career Highlights: Throughout his illustrious career, Antoine Stenger has lent his expertise to renowned companies in the pharmaceutical industry, including Pierre Fabre S.A. and P.F. Medicament. His work within these esteemed organizations has not only propelled his own success but has also contributed to advancements in medical science and technology.

Collaborations: Antoine Stenger has collaborated closely with industry peers such as Henri Cousse and Gilbert Mouzin, pooling their collective knowledge and expertise to bring innovative ideas to life. These collaborations have fostered a culture of creativity and shared learning, resulting in the development of groundbreaking solutions for complex medical challenges.

Conclusion: Antoine Stenger's unwavering commitment to innovation and his remarkable ability to transform ideas into tangible inventions have cemented his legacy as a trailblazer in the world of inventors. His pioneering spirit serves as a beacon of inspiration for future generations of innovators, driving them to reach new heights of creativity and impact in the realm of scientific discovery.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com